Observational studyClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Real-world clinical experience with osimertinib in advanced EGFR-mutated non-small cell lung cancer.
Observational study in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Therapeutic Impact of Third-generation Tyrosine Kinase Inhibitors on Lung Squamous Cell Carcinoma with Epidermal Growth Factor Receptor Mutations: A Case Description and Systematic Literature Review.Internal medicine (Tokyo, Japan) · 2026Pooled it
- First-line osimertinib in advancedESMO real world data and digital oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWe aimed to evaluate the effectiveness and safety of osimertinib as a first-line therapy in patients with advanced EGFR-mutated non-small cell lung cancer (aNSCLC) in a Spanish real-world setting.
methodsThis retrospective observational study was conducted at eight centers. The primary objective was to assess the effect of osimertinib on progression-free survival (PFS). The secondary objective was to evaluate the objective response rate (ORR), disease control rate (DCR), overall survival (OS), and drug toxicity.
resultsA total of 181 patients with aNSCLC were included in this study. The median PFS and OS were 15.8 (95% CI 12.5-19.0) and 29.3 (95% CI 21.1-37.5) months, respectively. An Eastern Cooperative Oncology Group Performance Status (ECOG PS) score ≥ 2 was associated with shorter PFS, whereas the presence of common EGFR mutations (exon 19 deletion and exon 21 L858R) was associated with longer PFS. Similarly, the age ≥ 70 years and an ECOG PS ≥ 2 were associated with a shorter OS, whereas the exon 19 deletion was associated with a longer OS. In addition, the overall ORR was 71.3% (CI 95% 64.7-77.9%), and the DCR was 87.8% (CI 95% 83.1-92.6%), with exon 19 deletion associated with a greater treatment response. Finally, 77% of the patients reported mild adverse reactions. Severe toxicity was not observed.
conclusionsThis study supports the effectiveness and tolerable safety profile of osimertinib as first-line treatment for patients with aNSCLC in a real-world setting. Exon 19 deletion appears to be a strong predictor of greater effectiveness in patients with aNSCLC.
Indexed as
Identifiers
40796995What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.